GlassScriptPhysician profile
Muhammad H Dogar
NPI 1851312649
$8,187.50
in general payments reported to CMS, 2019-2025
32 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $1,007 · 2021: $1,704 · 2022: $717 · 2023: $1,095 · 2024: $1,099 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,492 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,492.09 |
| Education | $102.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $804.30 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $803.40 | 2019-2025 | Lifevest |
| Abbott Laboratories | $780.21 | 2019-2025 | Aveir |
| Bayer Healthcare Pharmaceuticals INC. | $777.81 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $532.38 | 2021-2025 | Farxiga, Wainua |
| Bardy Diagnostics, INC. | $449.19 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $411.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $384.17 | 2021-2025 | Verquvo |
| Kestra Medical Technology Services, INC. | $333.92 | 2022-2025 | Assure Wcd |
| Glaxosmithkline, LLC. | $313.75 | 2022-2025 | Nucala, Trelegy Ellipta |
| Abiomed | $312.89 | 2019-2025 | |
| Cvrx, INC. | $274.51 | 2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $266.48 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $231.13 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.17 | 2019-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $197.20 | 2019-2021 | |
| Amgen INC. | $177.15 | 2019-2023 | Repatha |
| Edwards Lifesciences Corporation | $157.96 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $152.69 | 2022-2023 | Uptravi, Opsumit |
| Biotronik INC. | $122.61 | 2021-2022 | |
| Scpharmaceuticals INC. | $111.22 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $56.90 | 2023-2024 | Inpefa |
| Biogen, INC. | $47.39 | 2024 | Skyclarys |
| Terumo Medical Corporation | $40.78 | 2021 | |
| Philips North America LLC | $38.55 | 2025 | Ecc Solutions |
| Boston Scientific Corporation | $33.71 | 2019-2024 | Watchman Flx |
| Medtronic, INC. | $33.34 | 2023 | Mycarelink |
| Janssen Biotech, INC. | $29.01 | 2023 | Symtuza |
| Novo Nordisk INC | $27.04 | 2025 | Wegovy |
| Impulse Dynamics (USA) INC. | $26.51 | 2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $21.62 | 2020 | |
| B. Braun Interventional Systems INC. | $17.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Dogar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.